Pooled Data From BREEZE-AD1 and BREEZE-AD2 Examining the Efficacy and Safety of Baricitinib in Patients With Atopic Dermatitis and Atopic Comorbidities

From the 2020 Annual Meetings of the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American Academy of Dermatology (AAD), and Revolutionizing Atopic Dermatitis (RAD).
Clinically significant improvements observed in skin symptoms, itch, and sleep disturbance with baricitinib in adults with moderate to severe AD with comorbid atopic conditions.
Format: Microsoft PowerPoint (.ppt)
File Size: 189 KB
Released: July 27, 2020


Provided by Clinical Care Options.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

This educational activity is supported by educational grants from
AbbVie Inc.
Pfizer Inc.

Related Content

Expert slides from Clinical Care Options (CCO) on optimal management of inflammatory bowel disease (IBD), including ulcerative colitis, Crohn disease

Uma Mahadevan, MD William Sandborn, MD Released: September 22, 2020

A review on how new and emerging data in the management of atopic dermatitis will affect clinical practice: atopic dermatitis conference coverage from CCO

Andrew F. Alexis, MD, MPH Jonathan Silverberg, MD Released: September 21, 2020

Expert-authored commentary on investigational selective JAK inhibitors in atopic dermatitis treatment from Clinical Care Options (CCO)

Jonathan Silverberg, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Released: August 12, 2020 Expired: August 11, 2021

Efficacy, safety of baricitinib in patients with moderate to severe atopic dermatitis in BREEZE-AD5: atopic dermatitis conference coverage from CCO

Released: August 11, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.